WW International

Is WW International publicly traded?
Yes, WW International, Inc. is publicly traded on Nasdaq under the ticker symbol WW. The company was delisted during its Chapter 11 bankruptcy filing in May 2025, then relisted on Nasdaq on July 8, 2025, after emerging from bankruptcy. The company had previously been publicly traded since 2004.

Why did WW file for bankruptcy?
WW filed for Chapter 11 bankruptcy in May 2025 to restructure approximately $1.6 billion in debt. The company's debt burden, combined with the disruption caused by GLP-1 weight loss medications to its traditional behavioral business, made the debt unsustainable. The reorganization eliminated $1.15 billion in debt, reducing total debt to $465 million.

What is the difference between WW and Weight Watchers?
WW is the rebranded name for Weight Watchers International, adopted in 2018 to reflect the company's evolution from a sole focus on weight loss to broader health and wellness. The legal name of the company is WW International, Inc. The Weight Watchers brand name is still used in consumer-facing marketing.

How many subscribers does WW have?
WW had 2.5 million total end-of-period subscribers as of Q2 2026. This includes 2.29 million behavioral subscribers (down 24.6 percent year over year) and 197,000 clinical subscribers (up 55.7 percent year over year). Core+ subscribers were 541,000, up 13.9 percent year over year.

Who is the CEO of WW International?
WW International is currently led by an Interim Office of the Chief Executive, with Jon Volkmann (Chief Operations Officer) and Felicia DellaFortuna (Chief Financial Officer) sharing executive responsibilities. The previous CEO, Tara Comonte, departed after the company's emergence from bankruptcy in 2025. The company is searching for a permanent CEO.

What is WW's Clinical business?
WW's Clinical business, operated through its Sequence subsidiary, provides telehealth access to clinicians who can prescribe GLP-1 weight management medications, lab work, and ongoing medical supervision. Clinical subscription revenue was $39.9 million in Q2 2026, up 30.4 percent year over year, and accounted for 24.6 percent of total revenue.

What is WW's revenue?
WW reported Q2 2026 revenue of $162.3 million, down 14.2 percent from $189.2 million in Q2 2025. The decline was driven by a 22.7 percent drop in behavioral subscription revenue, partially offset by 30.4 percent growth in clinical subscription revenue. The company has reaffirmed its full-year 2026 revenue and adjusted EBITDA guidance.

WW International was founded in 1963 by Jean Nidetch, a Queens, New York homemaker who developed the Weight Watchers program based on her personal weight loss journey. Nidetch established the company to help others achieve weight loss through group support and structured programs. The company grew rapidly and went public in 1968.

In 1978, H.J. Heinz acquired Weight Watchers, and the company continued to grow under corporate ownership. In 2000, Weight Watchers was taken private by private equity investors. The company returned to public markets in 2004.

In 2018, the company rebranded to "WW" to reflect its evolution from a focus solely on weight loss to overall health and wellness. The rebrand was part of a strategy to position the company as a broader wellness brand, though it generated mixed reactions from longtime members.

In 2023, WW acquired Sequence, a telehealth platform that connects patients with clinicians for GLP-1 weight loss medications. The acquisition marked WW's entry into the clinical weight loss market, responding to the rise of drugs like Ozempic and Wegovy.

The rise of GLP-1 medications created significant pressure on WW's traditional behavioral business. In May 2025, WW filed for Chapter 11 bankruptcy protection to restructure its debt. The company had accumulated approximately $1.6 billion in debt. The reorganization plan eliminated $1.15 billion in debt, reducing total debt to $465 million and freeing up approximately $50 million in cash annually from lower interest expense. WW emerged from bankruptcy on June 24, 2025, and relisted on Nasdaq under the ticker WW on July 8, 2025.

Following the emergence from bankruptcy, CEO Tara Comonte departed. The company established an Interim Office of the Chief Executive led by Jon Volkmann (COO) and Felicia DellaFortuna (CFO). Dr. Kim Boyd was appointed Chief Medical Officer. The company also expanded its program to support women through menopause.

In Q2 2026, WW reported revenue of $162.3 million, down 14.2 percent year over year. Clinical subscription revenue grew 30.4 percent to $39.9 million, while behavioral subscription revenue declined 22.7 percent to $121.5 million. The company reduced its debt by $36.8 million during the quarter and generated positive operating cash flow of $24.3 million. WW reaffirmed its full-year 2026 revenue and adjusted EBITDA guidance.

WW International filed for Chapter 11 bankruptcy protection in May 2025, facing a mounting debt burden that GLP-1 revenue growth could not offset. The bankruptcy filing followed a turbulent period marked by disappointing financial results, staff cuts, and executive turnover. The company's stock fell below $1 for the first time in August 2024.

The rise of compounded GLP-1 medications created regulatory complexity for WW's Clinical business. Following the May 2025 FDA deadline prohibiting outsourcing facilities from compounding semaglutide, WW had to transition impacted Clinical members to alternative medications at higher price points. Some telehealth competitors continued offering compounded GLP-1s, creating uneven competitive conditions.

The company has faced executive turnover, with CEO Tara Comonte departing after the bankruptcy emergence. The company is currently led by an Interim Office of the Chief Executive, and the search for a permanent CEO is ongoing. The company's 10-Q filings note the risk that it may not appoint a new CEO with the required level of experience in a timely manner.